KPV
Research OnlyAlso known as: Lys-Pro-Val, Lysine-Proline-Valine, alpha-MSH(11-13), C-terminal alpha-MSH tripeptide
A naturally occurring tripeptide derived from the C-terminus of alpha-melanocyte-stimulating hormone (alpha-MSH). Preclinical studies demonstrate potent anti-inflammatory effects via NF-kB inhibition, but no human clinical trials have been conducted. Research has focused on inflammatory bowel disease and skin inflammation models.
Research Statistics
Alpha-MSH tripeptide fragment with predominantly preclinical IBD data and only one small human study; melanocortin anti-inflammatory mechanism proposed but not independently validated in humans.
Research Dossier
Overview
What is KPV and what does the research say?
Mechanism of Action
The proposed mechanisms of KPV are based on animal models and cell culture studies. No human mechanistic data exists.
How It Works (Simplified)
KPV acts as an “inflammation brake” that works at the cellular level through several pathways:
Blocks the master inflammation switch by preventing IkBa degradation. Keeps NF-kB trapped in cytoplasm, unable to turn on inflammatory genes.
Uses intestinal peptide transporter PepT1 for cellular uptake - unusual for peptides and suggests potential oral bioavailability.
Reduces production of inflammatory messengers (TNF-alpha, IL-1, IL-6, IL-8) while potentially increasing anti-inflammatory IL-10.
Unlike parent alpha-MSH, KPV doesn’t bind melanocortin receptors. Provides anti-inflammatory benefits without skin pigmentation changes.
Scientific Pathways
NF-kB Pathway Inhibition (Primary Anti-Inflammatory)
Inflammatory stimulus (LPS, TNF-alpha, IL-1)
|
IKK activation -> IkBa phosphorylation
|
[KPV BLOCKS HERE - stabilizes IkBa]
|
NF-kB remains sequestered in cytoplasm
|
Inflammatory gene transcription preventedPepT1-Mediated Uptake (Oral Bioavailability)
Oral KPV -> Intestinal epithelium -> PepT1 transporter -> Intracellular accumulation -> NF-kB/MAPK inhibitionKey Research: Dalmasso G et al. demonstrated PepT1-mediated uptake is essential for KPV’s anti-inflammatory effects in colitis models. PMID:18061177
Important Limitations
- Nearly all mechanistic studies from limited research groups
- Translation to human physiology is unconfirmed
- Optimal administration route for systemic effects unknown
- Bioavailability and pharmacokinetics in humans not characterized
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
What to Expect
Timeline based on observations from published studies. Individual responses may vary.
Based on preclinical data: NF-kB inhibition begins within hours of administration. Reduction in pro-inflammatory cytokine production (TNF-alpha, IL-1, IL-6) observed in cell studies. Animal colitis studies showed reduced inflammation markers within the first week.
Animal studies demonstrate sustained anti-inflammatory effects with continued administration. Improved intestinal barrier function and reduced immune cell infiltration observed in colitis models.
Preclinical models show ongoing suppression of inflammatory pathways. Oral bioavailability via PepT1 transporter enables sustained intestinal effects in animal studies.
Long-term effects in humans are completely unknown. No clinical trials have established duration of treatment, optimal dosing, or sustained efficacy. All timeline data is extrapolated from short-term animal studies.
Research-Based Observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Quality Checklist
Visual indicators to help evaluate KPV product quality
Good Signs (6 indicators)
Warning Signs (5 indicators)
Bad Signs (6 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Peptide Interactions
Known and theoretical interactions when combining KPV with other peptides. Based on published research and mechanistic considerations.
BPC-157
CompatibleBoth have anti-inflammatory properties through different mechanisms. KPV targets NF-kB pathway while BPC-157 acts via VEGF/angiogenesis. No known contraindications.
LL-37
CompatibleLL-37's antimicrobial properties may complement KPV's anti-inflammatory effects in wound healing contexts. Different immune modulation mechanisms.
Thymosin-Alpha-1
CompatibleBoth modulate immune function through different pathways. KPV inhibits NF-kB while Ta1 enhances T-cell and dendritic cell responses. May have complementary effects.
GHK-Cu
CompatibleKPV's anti-inflammatory effects may complement GHK-Cu's wound healing and collagen synthesis properties. Different target pathways.
Melanotan-II
CautionBoth derive from melanocortin family. Unlike full alpha-MSH or Melanotan-II, KPV lacks melanocortin receptor binding. However, theoretical pathway overlap warrants caution.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare KPV
KPV Calculators
Related Peptides
Alpha-Defensins
HNP-1, HNP-2, HNP-3 +5 more
A family of small cationic antimicrobial peptides (29-35 amino acids) that are key components of innate immunity in humans. Produced primarily by neutrophils (HNP-1 to 4) and Paneth cells (HD-5, HD-6), they exhibit broad-spectrum antimicrobial activity and immunomodulatory functions. Well-characterized biochemically with extensive research, though therapeutic development faces challenges.
Kristagen
EDG, Glu-Asp-Gly, Immune tripeptide
A synthetic tripeptide (Glu-Asp-Gly) developed by Russian scientist Vladimir Khavinson, claimed to regulate thymus function and support immune cell differentiation. No Western clinical validation exists; research is limited to Russian preclinical studies.
Lactoferricin
LFcinB, Lactoferricin B, LfcinB +1 more
An antimicrobial peptide derived from lactoferrin, a protein found in milk and other secretions. Shows broad-spectrum antimicrobial activity in laboratory studies. Research focuses on potential applications in infectious disease, food safety, and cancer. Primarily studied preclinically with very limited human clinical data. Not approved as a therapeutic by any regulatory agency.
LL-37
Cathelicidin, hCAP18, Human Cationic Antimicrobial Peptide 18 +3 more
The only human cathelicidin antimicrobial peptide, discovered at Karolinska Institute in Sweden (1995). A 37-amino acid peptide with broad-spectrum antimicrobial activity and immunomodulatory functions. Extensive mechanistic research supports roles in innate immunity, wound healing, and host defense.
Murepavadin
POL7080, RG7929
A first-in-class cyclic antimicrobial peptide targeting the LptD outer membrane protein of Pseudomonas aeruginosa. The first OMPTA (outer membrane protein targeting antibiotic) to reach clinical development. IV formulation discontinued due to nephrotoxicity; inhaled formulation continues Phase 3 development for cystic fibrosis and bronchiectasis patients.
Thymalin
Thymulin, Thymic Factor, Timalin +1 more
A thymic peptide complex developed in Russia and used clinically in the former Soviet Union for immunomodulation. Derived from calf thymus extract, it contains multiple peptides claimed to restore immune function. Approved in Russia since the 1970s but not recognized by Western regulatory agencies. Evidence comes primarily from Russian studies with limited Western replication.